Our top priority is the health and safety of our community. Visit our COVID-19 information page to see how we're responding to the public health emergency.

Support for you and your patients in one location.

PATIENT SERVICES FOR DOJOLVI

Have confidence in availability of DOJOLVI and access for your LC-FAOD patients

More than 400 patients in the US with LC-FAOD have been prescribed DOJOLVI (since FDA approval in June 2020)1

Ultragenyx is committed to patients with rare diseases, which is why we created UltraCare Patient Services for DOJOLVI—your patients’ guide throughout their treatment journeys.

Our UltraCare Guides have varied backgrounds, including social workers, healthcare professionals, and patient advocates, and are ready to help patients gain and maintain access to DOJOLVI.

UltraCare Guides help patients and their caregivers:

insurance coverage icon

Understand their
insurance coverage

patient support icon

Utilize patient support program resources, including help with billing and coding

financial assistance icon

Find and navigate available financial assistance and patient assistance programs that can help to cover co-pay and other out-of-pocket expenses

personalized counseling icon

Start and stay on DOJOLVI treatment through personalized counseling and education based on the recommendations, advice, and prescription of the patient’s healthcare team

HELP YOUR PATIENTS ENROLL IN ULTRACARE

Step 1: Complete the
Start Form with your patient.

Step 2: Fax the completed*
Start Form to 1-415-723-7474.

Contact our UltraCare Guides for additional support at 1-888-756-8657.

Visit UltraCare

*Please note that a completed form is required for patient enrollment.

Download DOJOLVI materials

Resources that may provide additional insight and support for you, your patients, and their families and caregivers

Filter Resources:

All

For Healthcare Providers

For Patients and Caregivers

For Spanish-speaking Patients and Caregivers

Back-to-School
Checklist


A tool to help your patients and their caregivers prepare for a discussion on managing DOJOLVI treatment during the upcoming school year.

DOJOLVI® (triheptanoin) Back-to-School Checklist

Download | Share

DOJOLVI
Dosing Flashcard
 


Important reminders to find your patient’s optimized DOJOLVI dose, as well as information on initiating and titrating DOJOLVI.

DOJOLVI® (triheptanoin) Dosing Flashcard

Download | Share

DOJOLVI
Start Form
 


Complete the Start Form to prescribe DOJOLVI.

DOJOLVI® (triheptanoin) Start Form

Download | Share

Annotated Guide for
the DOJOLVI Start Form
 


Instructions for how to complete the Start Form. This is a guide only. Do NOT complete and submit this document.

Annotated Guide for the DOJOLVI® (triheptanoin) Start Form

Download | Share

Understanding DOJOLVI
Dosing Brochure


A resource that clarifies the individualized approach to DOJOLVI dosing and administration.

Understanding DOJOLVI Dosing Guide

Download | Share

DOJOLVI Dosing Calculator
Quick Start Guide


Quick Start Guide designed to help you easily use the DOJOLVI Dosing Calculator.

DOJOLVI® (triheptanoin) Dosing Calculator Quick Start Guide

Download | Share

DOJOLVI
Patient Brochure
 


Information for your patients about LC-FAOD, DOJOLVI, and support available to them

DOJOLVI® (triheptanoin) Patient Brochure

Download | Share

DOJOLVI
Dosing Guide
 


Step-by-step instructions for storing, administering, and keeping track of DOJOLVI doses for your patients

DOJOLVI® (triheptanoin) Dosing Guide

Download | Share

Materials Compatibility Reference


A reference overview of materials that are compatible or incompatible to use with DOJOLVI

DOJOLVI® (triheptanoin) Materials Compatibility Reference

Download | Share

Daily
Dosing Tracker


A tool your patients can use to keep track of DOJOLVI doses

DOJOLVI® (triheptanoin) Daily Dosing Tracker

Download | Share

UltraCare Patient
Resource Guide


An overview of resources offered by UltraCare Patient Services

UltraCare Patient Resource Guide

Download | Share

LC-FAOD Disease
Monitoring Program for Patients


Learn more about a long-term
LC-FAOD observational study

UltraCare Patient Resource Guide

Download | Share

Descargar materiales de DOJOLVI

DOJOLVI
Folleto


Información para sus pacientes sobre LC-FAOD, DOJOLVI y el apoyo disponible para ellos

Folleto de DOJOLV(R)® (triheptanoin)

Descargar | Compartir

DOJOLVI
Guía de dosificación


Instrucciones paso a paso para almacenar, administrar y realizar un seguimiento de las dosis de DOJOLVI

Guía de dosificación de DOJOLVI™ (triheptanoin)

Descargar | Compartir

Patient Stories

Watch stories of patients and their caregivers navigating life with LC-FAOD and DOJOLVI.

Photo of Janelle, Michael, and Hanna living with carnitine-acylcarnitine translocase (CACT) deficiency

“We’re very fortunate we were able to get Hanna diagnosed and for the support from her healthcare team”

— Mike, caregiver of Hanna

“I really like working with my doctors as a team to actually understand what we’re going to do and why”

— Alexandra, age 19

Photo of Alexandra, living with long-chain 3-hydroxy-acyl-CoA dehydrogenase (LCHAD) deficiency
Photo of Daniel living with carnitine palmitoyltransferase II (CPT II) definicency

“Finding support has made it more manageable for me to live with CPT II”

— Daniel, age 22

Patient Guidance for Dosing and Administering DOJOLVI

Preparing DOJOLVI® (triheptanoin) Doses Videos

These demo videos support your patients on how to use the dosing components to prepare a DOJOLVI dose.

Watch Videos

Ver videos en Español

Patient Guidance for Proper Mixing

These videos demonstrate how to properly mix DOJOLVI into compatible semi-solid foods or liquids when preparing to take the medication orally.

Do not administer DOJOLVI alone to avoid gastrointestinal upset. For complete information on the preparation and administration of DOJOLVI orally or enterally via a silicone or polyurethane feeding tube, please refer to Section 2.4 of the full Prescribing Information.

Watch Videos

Mixing DOJOLVI® (triheptanoin) into food Video series

Reference:

  1. Data on file. Ultragenyx Hub Data: Prescribed Patients. Ultragenyx Pharmaceutical Inc.; 2022.

Stay Informed

Sign up to receive more information and updates about DOJOLVI (triheptanoin).

FOR US HEALTHCARE PROFESSIONALS

By submitting this form, you agree to allow Ultragenyx and its agents to collect the information provided and to be contacted directly by an Ultragenyx representative. Your information will not be used for any other purpose than for a representative to respond to your information request or for us to send you other DOJOLVI updates if you have registered to receive them.

Ultragenyx will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Ultragenyx and its agents. Ultragenyx will only use your information in accordance with its Privacy Policy.

INDICATION

DOJOLVI is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Feeding Tube Dysfunction

  • Feeding tube performance and functionality can degrade over time depending on usage and environmental conditions. In clinical trials, feeding tube dysfunction was reported in patients receiving triheptanoin. The contribution of DOJOLVI cannot be ruled out. Do not administer DOJOLVI in feeding tubes manufactured of polyvinyl chloride (PVC). Regularly monitor the feeding tube to ensure proper functioning and integrity.

Intestinal Malabsorption in Patients with Pancreatic Insufficiency

  • Pancreatic enzymes hydrolyze triheptanoin and release heptanoate as medium-chain fatty acids in the small intestine. Low or absent pancreatic enzymes may result in reduced absorption of heptanoate subsequently leading to insufficient supplementation of medium-chain fatty acids. Avoid administration of DOJOLVI in patients with pancreatic insufficiency.

ADVERSE REACTIONS

Gastrointestinal (GI)

  • The most common GI-related adverse reactions reported in the pooled safety population of Studies 1 and 2 were abdominal pain (abdominal discomfort, abdominal distension, abdominal pain, abdominal pain upper, GI pain) [60%], diarrhea [44%], vomiting [44%], and nausea [14%].

DRUG INTERACTIONS

Pancreatic Lipase Inhibitors

  • Co-administration of triheptanoin with a pancreatic lipase inhibitor (e.g., orlistat) may reduce exposure to the triheptanoin metabolite, heptanoate, and reduce the clinical effect of triheptanoin. Avoid co-administration of DOJOLVI with pancreatic lipase inhibitors.

USE IN SPECIFIC POPULATIONS

Pregnancy and Lactation

  • There are no available data on triheptanoin use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There is a pregnancy safety study for DOJOLVI. If a patient becomes pregnant while receiving DOJOLVI, healthcare providers should report DOJOLVI exposure by calling Ultragenyx Pharmaceutical Inc. at 1-888-756-8657.
  • There are no data on the presence of triheptanoin or its metabolites in human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the clinical need for DOJOLVI and any potential adverse effect on the breastfed infant from DOJOLVI or from the underlying maternal condition.

PATIENT COUNSELING INFORMATION

  • Instruct the patient or caregiver to read the FDA-approved patient labeling, which includes information on the appropriate oral or feeding tube preparation, administration, and storage.

You may report side effects to Ultragenyx Pharmaceutical Inc. at 1-888-756-8657 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


Please see full Prescribing Information for a complete discussion of the risks associated with DOJOLVI.

INDICATION

DOJOLVI is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Feeding Tube Dysfunction

  • Feeding tube performance and functionality can degrade over time depending on usage and environmental conditions. In clinical trials, feeding tube dysfunction was reported in patients receiving triheptanoin. The contribution of DOJOLVI cannot be ruled out. Do not administer DOJOLVI in feeding tubes manufactured of polyvinyl chloride (PVC). Regularly monitor the feeding tube to ensure proper functioning and integrity.

Intestinal Malabsorption in Patients with Pancreatic Insufficiency

  • Pancreatic enzymes hydrolyze triheptanoin and release heptanoate as medium-chain fatty acids in the small intestine. Low or absent pancreatic enzymes may result in reduced absorption of heptanoate subsequently leading to insufficient supplementation of medium-chain fatty acids. Avoid administration of DOJOLVI in patients with pancreatic insufficiency.

ADVERSE REACTIONS

Gastrointestinal (GI)

  • The most common GI-related adverse reactions reported in the pooled safety population of Studies 1 and 2 were abdominal pain (abdominal discomfort, abdominal distension, abdominal pain, abdominal pain upper, GI pain) [60%], diarrhea [44%], vomiting [44%], and nausea [14%].

DRUG INTERACTIONS

Pancreatic Lipase Inhibitors

  • Co-administration of triheptanoin with a pancreatic lipase inhibitor (e.g., orlistat) may reduce exposure to the triheptanoin metabolite, heptanoate, and reduce the clinical effect of triheptanoin. Avoid co-administration of DOJOLVI with pancreatic lipase inhibitors.

USE IN SPECIFIC POPULATIONS

Pregnancy and Lactation

  • There are no available data on triheptanoin use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There is a pregnancy safety study for DOJOLVI. If a patient becomes pregnant while receiving DOJOLVI, healthcare providers should report DOJOLVI exposure by calling Ultragenyx Pharmaceutical Inc. at 1-888-756-8657.
  • There are no data on the presence of triheptanoin or its metabolites in human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the clinical need for DOJOLVI and any potential adverse effect on the breastfed infant from DOJOLVI or from the underlying maternal condition.

PATIENT COUNSELING INFORMATION

  • Instruct the patient or caregiver to read the FDA-approved patient labeling, which includes information on the appropriate oral or feeding tube preparation, administration, and storage.

You may report side effects to Ultragenyx Pharmaceutical Inc. at 1-888-756-8657 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


Please see full Prescribing Information for a complete discussion of the risks associated with DOJOLVI.